PARAGON-HF: Novartis Hangs Onto Hope For Entresto In HFpEF
Despite Phase III miss, Novartis is hopeful that the totality of the evidence will secure it at least a limited label expansion to a sizable but harder to treat portion of the heart failure market than Entresto already serves.
You may also be interested in...
Keeping Track: Submissions From Sanofi, Merck, Novartis; Breakthrough Designations For GSK And Takeda
The latest news of submissions and expedited review designations from the Pink Sheet’s US FDA Performance Tracker
It's been a good week for the US company with its PCSK9 gene-silencing drug impressing at the American Heart Association meeting and reports that Novartis is close to making a bid.
The Phase III VICTORIA study evaluating the safety of the sGC stimulator met its primary endpoint.